Medicare would pay for skin substitute wound products using one national rate and one billing code. High-billing providers would face extra reviews before payment and prior approval rules. The FDA would also review how to speed up some tissue-product approvals without lowering safety standards.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Advanced Wound Care and Regenerative Medicine Access and Reform Act is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Latest action on H.R. 6852: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Who this affects: This bill mainly affects Medicare patients who need advanced wound care, the clinicians who treat them, and companies that make skin substitute or regenerative medicine products. Patients could see more consistent Medicare payment rules, but some care could take longer when prior authorization applies. Providers with very high Medicare billing for these products would face the biggest new oversight. Manufacturers and tissue banks could be affected by future Food and Drug Administration guidance on human cell and tissue product approvals.
Why this matters: Medicare now pays for skin substitute wound products in ways that can vary by product and care setting. This bill would make payment more uniform and add stronger checks on high-billing providers. That could reduce waste or fraud, but it could also add paperwork and delays for some wound-care practices. The FDA review could help some regenerative medicine products move through review faster, depending on how the agency carries it out.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
